Recro Pharma

Societal CDMO, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief.   It was founded in 2007 and headquartered in Malvern, Pennsylvania.

Recro Pharma recently received its second CRL from the FDA regarding its IV Meloxicam product candidate. As a result, the company has announced a restructuring of its Acute Care Segment.

Recro Pharma: Restructuring Points To Profits

This stock was pounded recently and offers a great entry point.

5 New Red Hot Stocks Trading Under $10 With Gigantic Upside Potential

Recro Pharma Inc. shares were crashing Monday in reaction to an adverse regulatory decision on its lead pain medication candidate that was announced late Friday.

More Pain For Recro Pharma: FDA Rejects Meloxicam NDA For Second Time

Shares of Recro Pharma Inc. plummeted 46% to pace all premarket decliners Monday.

Recro Pharma's stock plunges to pace premarket decliners after 2nd CRL for pain treatment

Recro Pharma, a smallcap U.S. pharma company has a Food and Drug Administration (FDA) decision on its main drug pending on March 24, 2019.

Upcoming FDA Decision Creates Upside And Catalyst For Recro Pharma

News for Recro Pharma Stock (REPH)